Netherlands Pharmaceutical Market Size (2024 - 2029)

The Netherlands Pharmaceutical Market is projected to experience growth over the forecast period, driven by factors such as an increase in healthcare spending, the presence of advanced research institutions, and a supportive government for biopharmaceutical operations. Despite the initial impact of the COVID-19 pandemic, which affected pharmaceutical sales due to lockdowns, the market is expected to stabilize and expand. The rising prevalence of diseases like cancer and diabetes further contributes to the market's potential growth. However, initiatives to reduce drug prices may challenge the profitability of pharmaceutical companies, and the high costs and failure rates associated with new product development could impede market expansion.

Market Size of Netherlands Pharmaceutical Industry

Netherlands Pharmaceutical Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Market Size (2024) USD 9.92 Billion
Market Size (2029) USD 14.24 Billion
CAGR (2024 - 2029) 7.50 %
Market Concentration Low

Major Players

Netherlands Pharmaceutical Market Major Players

*Disclaimer: Major Players sorted in no particular order

Netherlands Pharmaceutical Market Analysis

The Netherlands Pharmaceutical Market size is estimated at USD 9.92 billion in 2024, and is expected to reach USD 14.24 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the market in its early phase due to various lockdown regulations that were imposed. For instance, according to an article published by PubMed Central in January 2021, a cross-sectional study was performed, which showed that there was a considerable impact of the COVID-19 pandemic on both logistic procedures and services in the pharmacies of the Netherlands. The reduction in such services meant fewer pharmaceutical sales. Hence, the COVID-19 pandemic had a significant impact on the market initially. However, post pandemic the market studied is expected to have stable growth during the forecast period of the study.

The presence of world-class research institutes, a highly educated workforce, an excellent healthcare system, and an innovation-friendly government, combined with a central location, makes the country an ideal base for biopharmaceutical operations. Healthcare and medical spending have increased over the past few years, reflecting strong potential for new medicine development, infrastructure building, and new entry/expansion opportunities. At the same time, the government is taking various initiatives to lower the prices of pharmaceutical products, which is expected to have adverse effects on the profitability of pharmaceutical companies. The Netherlands is expected soon negotiate lowering drug prices with pharmaceutical companies.

As per the data published by the Dutch Cancer Society (KWF), in 2021, cancer was the leading cause of death in the Netherlands. According to the same data, in 2021, an estimated 44,996 persons died of cancer, out of which 24,266 were men, and 20,730 were women. Furthermore, according to the data published by the World Bank, in 2022, the prevalence of diabetes as a percentage of the population aged between 20 and 79 was 4.5% in the Netherlands in 2021. Hence with the increasing burden of various diseases, it is expected that there will be steady growth in the market.

Therefore, owing to the aforementioned factors, the market is anticipated to witness growth over the forecast period. However, the high failure rate and developing cost of new products are likely to impede the growth of the market.

Netherlands Pharmaceutical Industry Segmentation

Pharmaceuticals are referred to as prescribed and non-prescribed drugs. These medicines can be bought by an individual with or without the doctor's prescription and are safe for consumption for various illnesses with or without the doctor's consent. The report also covers an in-depth analysis of qualitative and quantitative data. The Dutch pharmaceutical market is segmented by ATC/therapeutic class (alimentary tract and metabolism, blood and blood-forming organs, cardiovascular system, dermatological drugs, genitourinary system and reproductive hormones, systemic hormonal preparations, excluding reproductive hormones and Insulins, antiinfectives for systemic use, antineoplastic and immunomodulating agents, musculoskeletal system, nervous system, antiparasitic products, insecticides and repellents, respiratory system, sensory organs, and various ATC structure), and mode of dispensing (Prescription and OTC). The report offers values in USD million for all the above-mentioned segments.

By ATC/Therapeutic Class
Alimentary Tract and Metabolisma
Blood and Blood-forming Organs
Cardiovascular System
Dermatological Drugs
Genitourinary System and Reproductive Hormones
Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins
Antiinfectives for Systemic Use
Antineoplastic and Immunomodulating Agents
Musculoskeletal System
Nervous System
Antiparasitic Products, Insecticides, and Repellents
Respiratory System
Sensory Organs
Various ATC Structures
By Mode of Dispensing
Prescription
OTC
Need A Different Region Or Segment?
Customize Now

Netherlands Pharmaceutical Market Size Summary

The Netherlands pharmaceutical market is poised for significant growth over the forecast period, driven by a combination of factors including a robust healthcare system, a highly educated workforce, and a government that fosters innovation. The country's strategic location and the presence of world-class research institutes make it an attractive hub for biopharmaceutical operations. Despite the initial setbacks caused by the COVID-19 pandemic, which impacted pharmaceutical sales due to lockdowns, the market is expected to recover and expand steadily. The increasing burden of chronic diseases such as cancer and cardiovascular conditions, along with rising healthcare expenditures, underscores the demand for new medicine development and infrastructure enhancements. However, government initiatives aimed at reducing drug prices may pose challenges to the profitability of pharmaceutical companies operating in the region.

The market landscape is characterized by moderate fragmentation, with several major players holding significant market shares. Companies like Abbott Laboratories, AbbVie Inc., and AstraZeneca PLC are actively engaging in acquisitions and joint ventures to strengthen their positions. The market is also witnessing a surge in product approvals and new drug launches, particularly in the prescription segment, which is driven by the rising prevalence of infectious diseases and chronic conditions. The introduction of new prescription-based drugs, such as Sanofi's Enjaymo and Tezspire, highlights the dynamic nature of the market. Despite challenges such as high product development costs and regulatory scrutiny, the Netherlands pharmaceutical market is expected to continue its growth trajectory, supported by ongoing research and development activities and increasing awareness of health issues among the population.

Explore More

Netherlands Pharmaceutical Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Presence of Better Research Institutes, Excellent Healthcare System, and an Innovation-friendly Government

      2. 1.2.2 Rising Cases of Chronic Diseases

    3. 1.3 Market Restraints

      1. 1.3.1 High Failure Rate and Developing Cost of New Products

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By ATC/Therapeutic Class

      1. 2.1.1 Alimentary Tract and Metabolisma

      2. 2.1.2 Blood and Blood-forming Organs

      3. 2.1.3 Cardiovascular System

      4. 2.1.4 Dermatological Drugs

      5. 2.1.5 Genitourinary System and Reproductive Hormones

      6. 2.1.6 Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins

      7. 2.1.7 Antiinfectives for Systemic Use

      8. 2.1.8 Antineoplastic and Immunomodulating Agents

      9. 2.1.9 Musculoskeletal System

      10. 2.1.10 Nervous System

      11. 2.1.11 Antiparasitic Products, Insecticides, and Repellents

      12. 2.1.12 Respiratory System

      13. 2.1.13 Sensory Organs

      14. 2.1.14 Various ATC Structures

    2. 2.2 By Mode of Dispensing

      1. 2.2.1 Prescription

      2. 2.2.2 OTC

Netherlands Pharmaceutical Market Size FAQs

The Netherlands Pharmaceutical Market size is expected to reach USD 9.92 billion in 2024 and grow at a CAGR of 7.5% to reach USD 14.24 billion by 2029.

In 2024, the Netherlands Pharmaceutical Market size is expected to reach USD 9.92 billion.

Netherlands Pharmaceutical Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)